Advertisements


We are Sorry, This Page doesn't Exist


Analysts All In On Transportation Stocks; Transition To Services Spending No Threat

A couple of bullish reports this week highlight reasons to favor transportation stocks moving forward. The outlooks call for favorable freight fundamentals around demand, utilization and pricing to remain in place for the foreseeable future. read more.....»»

Category: blogSource: benzingaMar 19th, 2021

GSEO remains competitive for Apple orders, say sources

Taiwan-based optical lens module maker Genius Electronic Optical (GSEO), despite pricing competition from China-based makers, especially Sunny Optical Technology, will remain competitive for orders from Apple, according to industry sources......»»

Category: topSource: digitimesMar 9th, 2020

Metals Stocks: Gold edges lower, but remains underpinned by falling bond yields

Gold futures edge lower Wednesday as equities rally, dulling its haven appeal, but the yellow metal remains underpinned as government bond yields remain under pressure in the wake of an emergency interest rate cut a day earlier by the Federal Reserve......»»

Category: topSource: marketwatchMar 4th, 2020

Market Extra: Dow slides into correction territory as stocks remain under pressure on coronavirus fears

Another sharp fall for U.S. stocks on Thursday saw major indexes fall or at least dip into correction territory, marking a drop of more than 10% from all-time highs. Here’s where major indexes would need to close to formally mark a correction......»»

Category: topSource: marketwatchFeb 27th, 2020

Roche and Gilead Losing Patent Protection on Top Sellers

Seven pharma companies face generic competition for medications that generated high U.S. sales in 2018Related Stocks: RHHBY, GILD, PFE, AMGN, GSK, INDV,.....»»

Category: blogSource: gurufocusDec 27th, 2019

Large-size polarizer pricing to remain under downward pressure in 2020

Prices of lar.....»»

Category: topSource: digitimesDec 19th, 2019

Capitol Report: Pelosi’s drug-pricing bill passes House, but pharma stocks are up as it’s unlikely to become law

The Democratic-led House on Thursday passes the party’s signature bill that aims to lower drug prices, as Democrats continue to make an effort to show that they’re not solely focused on impeaching President Donald Trump......»»

Category: topSource: marketwatchDec 12th, 2019

Capitol Report: Pelosi’s drug-pricing bill set to pass House on Thursday, but pharma stocks are up as it’s unlikely to become law

Top Democratic lawmakers say Thursday that the House in the coming days will pass their signature bill that aims to lower drug prices, as they make an effort to show that they’re not solely focused on impeaching President Donald Trump......»»

Category: topSource: marketwatchDec 11th, 2019

Market Snapshot: Stocks remain under pressure after Trump threatens to raise tariffs if China trade talks languish

U.S. stock-index futures head lower Wednesday morning as doubts persist about progress toward a U.S.-China trade deal despite encouraging earnings from some retailers. ......»»

Category: topSource: marketwatchNov 20th, 2019

Macquarie warns about pricing pressure among airlines from Southwest competition

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 29th, 2019

Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing

Shares of health companies were down Monday, with both the Health.....»»

Category: topSource: marketwatchJul 8th, 2019

Pharmas Acknowledge Drug Pricing Controversies As A Business Risk

In Response To Shareholder Pressure, Pharma Companies Begin To Acknowledge Drug Pricing Controversies As A Business Risk Second-year shareholder resolutions highligh.....»»

Category: blogSource: valuewalkJun 20th, 2019

Market Snapshot: Stock market falls, set for worst weekly skid of 2019 as higher China tariffs kick in

U.S. stocks remain under pressure, with major indexes heading for their worst weekly return this year after the Trump administration raised import duties on $200 billion in Chinese goods......»»

Category: topSource: marketwatchMay 10th, 2019

Stocks seen opening lower after Fed move, earnings reports

Stocks remain under pressure early Thursday with earnings reports pouring in.....»»

Category: topSource: foxnewsMay 2nd, 2019

Raymond James Expects Johnson & Johnson"s Growth To Accelerate Into 2020

Johnson & Johnson’s (NYSE: JNJ) bottom line continues to be come under pressure from forex and generic competition, and the company faces sentiment-related headwinds, according to Raymond James. Latest Ratings for JNJ .....»»

Category: blogSource: benzingaMar 25th, 2019

Market Snapshot: Dow poised to extend longest losing streak in a year as earnings fail to excite, bond yields rise

U.S. stocks remain under pressure on Wednesday, as investors grapple with a mixed bag of earnings reports and bond yields that have been steadily climbing for the past six sessions......»»

Category: topSource: marketwatchApr 25th, 2018

Higher interest rates and rising costs are a bad brew for stocks

Stocks are facing the double headwinds of rising interest rates and rising input costs, which could slow down earnings growth and pressure margins......»»

Category: topSource: moneycentralApr 24th, 2018

Cloud Competition: Morgan Stanley Downgrades Fortinet, Raises Palo Alto Networks" Price Target

Public cloud stocks have underperformed the broader market in recent years, and the market is only pricing in 5-percent topline growth through the end of the decade, according to an industrywide Morgan Stanley report. Latest Rati.....»»

Category: blogSource: benzingaApr 11th, 2018

Oracle Corp: Tech Bounce Opportunity With 20%+ Upside

Tech stocks have been beaten up since peaking on March 12. An escalating trade war and privacy issues remain headwinds, and present a bargain-hunting opportunity. A powerful stock screene.....»»

Category: blogSource: valuewalkApr 7th, 2018

Drug Prices Too High? Don’t Blame Rebates. Blame the FDA Approval Process

Both biotech and pharma may soon come under a pricing attack, and it could endanger future research initiatives and the flow of new drugs to marketRelated Stocks: ESRX, VRTX,.....»»

Category: dealsSource: nytMay 10th, 2018